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Abstract
The aim of this work was to study the effect of two different pre-treatments, high temperature (100 °C, 5 min) and high 
pressure (600 MPa, 3 min), on the potential of the enzymes papain, collagenase and Alcalase® to generate bioactive 
hydrolysates containing dipeptidyl peptidase-IV- (DPP-IV; EC 3.4.14.5) and prolyl endopeptidase- (PEP; EC 3.4.21.26) 
inhibitory peptides from bovine lung. Both pre-treatments resulted in an increase in the degree of hydrolysis over a 24 h 
period (P < 0.001) and significantly increased the DPP-IV- and PEP-inhibitory activities of the generated hydrolysates (P 
< 0.001). Generated hydrolysates included an Alcalase hydrolysate of pressure-treated bovine lung, which was the most 
active, and showed DPP-IV and PEP half-maximal inhibitory concentration (IC50) values of 1.43 ± 0.06 and 3.62 ± 0.07 mg/
mL, respectively. The major peptides contained in this hydrolysate were determined by liquid chromatography–tandem 
mass spectrometry, and results demonstrated that bovine lung is a good substrate for the release of bioactive peptides 
when proper pre-treatment and enzymatic treatment are applied.
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Introduction
Bioactive peptides consist of short sequences of amino 
acids encrypted within the sequence of a parent protein, 
which may be released by fermentation or hydrolysis 
using microorganisms, enzymes or acids (Korhonen and 
Pihlanto, 2006). Several studies in the past decade have 
demonstrated that peptides can be biologically active 
and may therefore serve as potential therapeutic agents 
in the body (Agyei and Danquah, 2011). The majority of 
the biologically active peptides identified to date can 
be found in the BIOPEP database (Minkiewicz et al., 
2008) and include antimicrobial, dipeptidyl peptidase-IV 
(DPP-IV; EC 3.4.14.5), angiotensin-I-converting enzyme 
(ACE-I; EC 3.4.15.1) and prolyl endopeptidase (PEP; 
EC 3.4.21.26)-inhibitory peptides, as well as antioxidant 
peptides (Nedjar-Arroume et al., 2008; Di Bernardini et al., 
2012; Bah et al., 2013; Lafarga and Hayes, 2014).
Human PEP is a serine peptidase, which digests a variety 
of proline-containing small peptides, including hormones, 
neuroactive peptides and various cellular factors (García-
Horsman et al., 2007). Although PEP is found in the central 
nervous system (CNS), the testis, skeletal muscle, kidney, 
liver and lung (Yaron et al., 1993), the one found in the CNS 
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is the main pharmacological target. Most of the published 
PEP inhibitors are chemically synthesised compounds based 
on the N-acyl-l-prolyl-pyrrolidine structure (Wilson et al., 
2011). However, a number of naturally occurring peptidic PEP 
inhibitors have been reported (Wilson et al., 2011). Although 
no physiological effect has been reported after administration 
of PEP-inhibitory hydrolysates or peptides to date, several 
studies carried out using animal models demonstrated the 
anti-amnestic and the memory- and cognition-enhancing 
properties of PEP inhibitors (Morain et al., 2002; Cheng et al., 
2005; Lawandi et al., 2010). Furthermore, transport of a PEP-
inhibitory peptide across the blood–brain barrier was recently 
demonstrated using a transcytosis model (Hayes et al., 
2015). In addition, both PEP and DPP-IV have been recently 
associated with externalising and aggressive behaviours in 
normal and autistic adolescents as a result of these peptidases 
cleaving behavioural neuropeptides (Frenssen et al., 2015). 
Human DPP-IV also degrades the incretin hormones such 
as glucagon-like peptide 1 and gastric inhibitory peptide, 
which aid the physiological control of postprandial blood 
glucose concentration in the body (Drucker, 2006). DPP-IV 
is expressed in a variety of tissues, primarily on endothelial 
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Materials and methods
Materials and reagents
Trichloroacetic acid (TCA), formic acid (FA), acetonitrile 
(ACN), collagenase from Clostridium histolyticum, papain 
from Carica papaya and valproic acid were supplied by Sigma 
Aldrich (Dublin, Ireland). Alcalase® 2.4 L FG was kindly 
supplied by Novozymes (Bagsvaerd, Denmark). The DPP-IV 
inhibitor screening assay kit, containing the DPP-IV inhibitor 
and positive control sitagliptin, was supplied by Cambridge 
BioSciences (Cambridge, England, UK). The PEP assay kit 
was supplied by Tebu-Bio Ltd. (Peterborough, England, UK). 
All other chemicals used were of analytical grade.
Sample preparation and pre-treatment
The three animals slaughtered were of Charolais cross heifer 
breed and were aged between 23 and 24 mo at the time of 
slaughter. One whole lung from each animal was collected 
at the time of slaughter under hygienic conditions at the 
abattoir at the Teagasc Food Research Centre, Ashtown, 
Dublin, Ireland. Collected lungs were frozen, freeze-dried 
using an industrial-scale FD 80 model freeze-drier (Cuddon 
Engineering, Marlborough, New Zealand), milled and stored 
at -20 °C until further use, as shown in Figure 1.
Three bovine lung samples were used. One lung sample 
was left untreated and was labelled as UT. The UT substrate 
solution was prepared by suspending the dried, untreated 
lung co-product in MilliQ purified water at a concentration of 
10 g/L at a total volume of 500 mL. Heat-treated samples were 
prepared by suspending the dried, untreated lung co-product 
in MilliQ purified water at a concentration of 10 g/L at a total 
volume of 500 mL and immediately immersing in a boiling 
water bath for 5 min. The samples were then chilled with tap 
water for 10 min and labelled as HT. Dried lung samples that 
were treated with pressure were transferred into polyethylene 
bags and vacuum-sealed. High-pressure pre-treatment was 
performed in the pressurising chamber of a Hiperbaric 135 
equipment (Hiperbaric, Burgos, Spain) at 600 MPa for 3 min, 
and samples were labelled as PT. After pressure treatment, 
PT samples were immediately stored at -20 °C for a maximum 
of 24 h. The high-pressure substrate solutions were prepared 
by suspending the pressure-treated dried samples in MilliQ 
purified water at a concentration of 10 g/L at a total volume of 
500 mL.
The total protein content of the UT, HT and PT lung samples 
was determined using a LECO FP628 Protein analyser 
(LECO Corp., St. Joseph, MI, USA) based on the Dumas 
method and according to Association of Official Analytical 
Chemists (AOAC) method 992.15 (AOAC, 1990). The protein 
content of enzymatic hydrolysates was assessed using the 
same method. The conversion factor of 6.25 was used to 
and epithelial cells (Lambeir et al., 2003). However, DPP-
IV inhibitors have been suggested to act locally in the 
gastrointestinal tract by inhibiting intestinal DPP-IV (Waget 
et al., 2011). The use of bioactive hydrolysates containing 
PEP and DPP-IV inhibitors, as well as their inclusion into 
food products, shows potential in the realm of functional 
food research as a strategy for potential prevention of 
mental health disorders and type-2 diabetes through 
tailored diet.
Co-products from the meat processing industry constitute 
an excellent source of high-quality proteins including 
collagen. Recently, Darine et al. (2010) determined the 
collagen content of bovine lung, which was approximately 
4.1% (w/w). Collagen is used extensively in the 
pharmaceutical, cosmetic, biomedical and food industries. 
A number of bovine collagen–derived hydrolysates with 
health-promoting properties, including Peptan® B 5000 
HD (Rousselot SAS, Angoulême, France), are currently 
available. In addition, bovine lung has been used as 
a substrate for the release of bioactive peptides with 
antioxidant activities (Damgaard et al., 2015) and has 
been also suggested to be a potential source of novel 
PEP- and DPP-IV-inhibitory peptides, mainly because of 
its high collagen concentration (Minkiewicz et al., 2011; 
Lafarga et al., 2014, 2015). However, due to its structure, 
collagen is not easily accessible for enzymatic hydrolysis. 
High-pressure and heat treatments have been previously 
used before enzymatic hydrolysis of collagen to facilitate 
the destabilisation of its structure and the exposure of the 
inner sites of the protein to the proteolytic enzyme (Zhang 
et al., 2013). Pressure and temperature pre-treatments 
have also been used successfully in the release of peptides 
with other bioactivities, including antioxidant peptides and 
inhibitors of ACE-I from different animal and plant sources 
(Quirós et al., 2007; Singh and Ramaswamy, 2014; Garcia-
Mora et al., 2015; Girgih et al., 2015).
The aim of this study was to generate hydrolysates with 
PEP- and DPP-IV-inhibitory bioactivities from bovine lung 
using the enzymes Alcalase, collagenase and papain, in 
addition to studying the effect of heat and pressure pre-
treatments on the DPP-IV- and PEP-inhibitory activities of 
bovine lung hydrolysates. Hydrolysates generated using 
Alcalase, collagenase and papain after pre-treatment 
with temperature or pressure were screened for their 
ability to inhibit the enzymes PEP and DPP-IV in vitro. 
The concentration of hydrolysate needed to inhibit 
the activity of PEP and DPP-IV by 50% (half-maximal 
inhibitory concentration [IC
50] value) was determined for 
the generated protein hydrolysates, and a number of 
peptides were identified using liquid chromatography (LC) 
and mass spectrometry (MS) in an Alcalase hydrolysate 
obtained from high pressure–treated bovine lung.
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DPP-IV inhibition assay
This assay was carried out using a DPP-IV inhibitor screening 
assay kit in accordance with the manufacturer’s instructions. 
Fluorescence intensity was recorded with a FLUOstar Omega 
microplate reader (BMG Labtech, Ortenburg, Germany) 
using an excitation wavelength of 355 nm and an emission 
wavelength of 460 nm. Sitagliptin was used as a positive 
control and it has a known IC
50 value of 19 nM (Thomas 
et al., 2008). The IC50 values of the enzymatic hydrolysates 
generated in this study were determined by plotting the 
percentage of inhibition as a function of the concentration of 
test hydrolysate (0.5, 1.0, 2.0, 4.0 and 5.0 mg/mL).
PEP-inhibitory assay
The PEP-inhibitory assay was carried out using a fluorogenic 
PEP assay kit in accordance with manufacturer’s instructions. 
Fluorescence intensity was recorded with a FLUOstar 
Omega microplate reader (BMG Labtech) using an excitation 
wavelength of 355 nm and an emission wavelength of 460 nm. 
Valproic acid was used as a positive control and it has an 
IC
50 value of 1–2 mM (Cheng et al., 2005). PEP IC50 values 
were determined for UT, PT and HT samples hydrolysed with 
Alcalase, collagenase and papain by plotting the percentage 
of PEP inhibition as a function of the concentration of test 
hydrolysate (0.5, 1.0, 2.0, 4.0 and 5.0 mg/mL).
Peptide identification by LC-MS/MS
The peptidic content of the Alcalase hydrolysate of PT 
lung proteins, which showed the highest bioactivity values, 
was analysed by LC-MS/MS using a Thermo Scientific 
Q-ExactiveTM mass spectrometer connected to a Dionex 
UltiMate® 3000 RSLCnano LC System. The freeze-dried 
sample was suspended in 0.1% FA in high-performance LC-
grade water at a concentration of 1 mg/L and cleaned using 
Millipore® C18 ZipTips before characterisation. The sample 
was then loaded onto a Biobasic Picotip Emitter (120 mm 
length, 75 mm internal diameter) packed with Reprocil-Pur 
C18 (1.9 mm) reversed phase medium and was separated 
using an increasing ACN gradient over 60 min at a flow rate 
of 250 nL/min. The mass spectrometer was operated in a 
positive ion mode with a capillary temperature of 220 °C and a 
potential of 2.3 kV applied to the emitter. All data were acquired 
by operating in an automatic data-dependent switching mode. 
A high-resolution – 70,000 full width at half maximum – MS 
scan (m/z 300 to m/z 1,600) was performed using Q-Exactive 
mass spectrometer to select the 12 most intense ions before 
MS/MS analysis using higher-energy collisional dissociation.
The raw data were de novo sequenced and searched against 
the bovine subset of the UniProtKB/Swiss-Prot database using 
the search engine of PEAKS Studio 7 for peptides cleaved with 
no specific enzyme. At least one unique peptide was required 
to identify a protein. Each peptide used for protein identification 
convert total nitrogen to protein. Moisture and ash content 
were determined gravimetrically in accordance with previously 
described methods (Kolar, 1992).
Amino acid composition analysis
For total and free amino acid composition analysis, the 
dried bovine lung (UT sample) was hydrolysed in 6 M HCl at 
110 °C for 23 h following the method of Hill (1965). Briefly, 
the sample was de-proteinised by mixing equal volumes of 
24% (w/v) TCA and sample. It was then allowed to stand 
for 10 min before centrifuging at 14,400 × g for 10 min 
in an MSE Micro Centaur Plus centrifuge (MSE, London, 
UK). The supernatant was removed and diluted with 
0.2 M sodium citrate buffer (pH 2.2) to give approximately 
250 nmol of each amino acid residue. The sample was then 
diluted 1:1 with the internal standard, norleucine, to give 
a final concentration of 125 nmol/mL. Amino acids were 
quantified using a Jeol JLC-500/V amino acid analyser 
(Jeol Ltd., Garden city, Herts, UK) fitted with a Jeol Na+ 
high-performance cation exchange column.
Enzymatic hydrolysis
The UT, PT and HT bovine lung samples were hydrolysed 
in triplicate separately with papain, Alcalase or collagenase. 
The sample solutions were pre-incubated at the optimal 
temperature and pH of each enzyme for 10 min before addition 
of the enzyme: 65 °C and pH 6.5 for papain, 37 °C and pH 7.5 
for collagenase and 60 °C and pH 9.5 for Alcalase. Agitation 
was kept constant at 350 rpm. Once the optimum conditions 
were achieved, the enzymes were added in a substrate-to-
enzyme ratio of 100:1 (w/w). After 24 h, the enzymes were 
heat-deactivated at 95 °C for 10 min in a water bath. The pH 
was kept constant at the optimum for each enzyme using 
0.1 M NaOH.
The degree of hydrolysis (DH) was calculated using the pH-
stat technique after 1, 30, 60, 120, 240, and 1,440 min (Adler-
Nissen, 1986). The DH was calculated using the equation:
tot
1 1 1DH 100 %,B
P
B N M hα= × × × × ×
where B (mL) is the volume of NaOH consumed, NB is the 
normality of the NaOH used, 1α  is the average degree of 
dissociation of the a-amino groups related with the pK of the 
amino groups at particular pH and temperatures, MP (g) is the 
amount of protein in the reaction mixture, and htot (meq/g) is 
the sum of the millimoles of individual amino acids per gram 
of protein associated with the source of protein used in the 
experiment. Values for htot and 
1
α  were obtained from the study 
conducted by Adler-Nissen (1986).
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Results
Protein content and amino acid composition
The protein content of whole bovine lung was 19.2 ± 0.4%. 
The amino acid composition of bovine lung proteins was 
calculated, and the results are shown in Table 1. Whole bovine 
lung was cut into smaller pieces of approximately 3 × 3 × 3 cm 
and freeze-dried as shown in Figure 1. The total protein, ash 
and moisture contents of the dried lung were 71.6 ± 0.3%, 
4.2 ± 0.1% and 13.2 ± 0.6%, respectively. In addition, bovine 
lung samples were hydrolysed individually with the enzymes 
papain, collagenase and Alcalase. These hydrolysates were 
freeze-dried and were found to contain 70.3 ± 0.3, 60.0 ± 0.1 
and 68.0 ± 0.2% protein; and 7.31 ± 0.02, 13.69 ± 0.12 and 
9.87 ± 0.11% moisture; and 7.27 ± 0.05, 6.21 ± 0.07 and 
14.38 ± 0.26% ash, respectively.
In vitro assessment of bioactivity: effect of pre-treatment 
on the release of DPP-IV- and PEP-inhibitory peptides
The papain, collagenase and Alcalase hydrolysates of UT 
bovine lung were assessed for their in vitro DPP-IV- and PEP-
inhibitory activities, and the results are shown in Figure 2. 
Results demonstrated that Alcalase was the most effective 
enzyme in releasing DPP-IV-inhibitory peptides from the 
met specific PEAKS parameters (only peptide scores that 
corresponded to a false discovery rate of ≤1% were accepted 
from the PEAKS database search). The sample was run three 
times, and the results shown are the combined technical 
replicates. Peptide sequences, their positions inside the parent 
proteins, their observed masses and their retention times were 
provided by the PEAKS Studio software.
Statistical analysis
The statistical analyses were performed using SPSS for 
Windows (v. 18.0) (IBM Corp., Armonk, NY, USA). Normality 
of the data was tested using the Kolmogorov–Smirnov 
test, and the data were logarithmically transformed when 
needed. A univariate general linear model was used to test 
the different bioactivity responses observed for DPP-IV 
and PEP, with the effects of pre-treatment, enzyme and the 
interaction of both factors included in the model and Tukey’s 
honest significant difference (HSD) post hoc test to check 
for statistical differences. Repeated-measures general 
linear model was used to test the response of the DH with 
time, time × pre-treatment, time × enzyme and time × pre-
treatment × enzyme interactions included in the model. Post 
hoc Scheffe test was used to test for statistically significant 
differences when needed. The criterion for statistical 
significance was P < 0.05.
Figure 1. Schematic representation of the procedure followed for 
the generation of bioactive peptides from bovine lung. UT, HT and 
PT refer to untreated, heat-treated and high pressure-treated sam-
ples, respectively. MWCO = molecular weight cut-off; HPLC-MS/MS 
= high-pressure liquid chromatography-tandem mass spectrometry; 
DPP-IV = dipeptidyl peptidase-IV; PEP = prolyl endopeptidase.
Table 1. Total and free amino acid contents of bovine lung proteins
Amino acid Total amino acids 
(mg/100 g) ± s.d.
Free amino acids 
(mg/100 g) ± s.d.
Met 1.29 ± 0.03 0.77 ± 0.02
Asx 4.49 ± 0.09 8.31 ± 0.17
Thr 2.11 ± 0.04 3.30 ± 0.07
Ser 2.46 ± 0.05 4.34 ± 0.09
Glx 6.81 ± 0.14 28.88 ± 0.58
Gly 5.86 ± 0.12 26.45 ± 0.53
Ala 4.04 ± 0.08 6.25 ± 0.13
Cys 1.28 ± 0.03 1.79 ± 0.09
Val 3.44 ± 0.07 4.41 ± 0.09
Ile 1.81 ± 0.04 2.26 ± 0.05
Leu 4.65 ± 0.09 4.46 ± 0.09
Tyr 1.43 ± 0.03 2.31 ± 0.05
Phe 2.54 ± 0.05 2.96 ± 0.06
His 1.88 ± 0.04 1.40 ± 0.03
Lys 3.74 ± 0.07 4.49 ± 0.09
Arg 3.69 ± 0.07 4.07 ± 0.08
Pro 3.51 ± 0.07 3.15 ± 0.06
16
Irish Journal of Agricultural and Food Research
hydrolysates generated using papain, collagenase and 
Alcalase after heat and high-pressure pre-treatments. 
Results demonstrated that the DPP-IV-inhibitory activity of 
the hydrolysates was significantly influenced by pre-treatment 
(P < 0.001), enzyme (P < 0.001) and the interaction of both 
factors (P < 0.05). As mentioned earlier, Alcalase generated 
the most active hydrolysate from the UT samples. This 
trend was also observed after hydrolysis of both HT and PT 
samples. Alcalase hydrolysates of PT and HT bovine lung 
were found to inhibit the enzyme DPP-IV by 43.70 ± 0.63% 
and 28.28 ± 1.18%, respectively, when tested at a sample 
concentration of 1 mg/mL. The IC
50 values of these two 
hydrolysates were 1.43 ± 0.06 and 2.18 ± 0.03 mg/mL, 
respectively. Both pre-treatments, heat and high pressure, also 
increased the activity of hydrolysates generated using papain 
and collagenase. The IC50 values of papain hydrolysates of 
PT and HT samples were lower when compared to that of 
the papain hydrolysate of UT samples (P < 0.05). In addition, 
collagenase hydrolysates of PT and HT samples were also 
more active when compared to the UT sample, and the IC50 
values were 2.60 ± 0.18 and 2.70 ± 0.01 mg/mL, respectively.
PEP-inhibitory activity was also significantly influenced by pre-
treatment (P < 0.001), enzyme (P < 0.05) and the interaction 
of both factors (P < 0.05). As mentioned earlier, collagenase 
generated the most active PEP-inhibitory hydrolysate after 
hydrolysis of the UT lung samples (Figure 2). Again, this 
trend was maintained after hydrolysis of both HT and PT 
lung samples. The use of heat and high pressure as pre-
treatments significantly increased the PEP-inhibitory activity 
of the Alcalase hydrolysates of lung proteins (P < 0.05). No 
significant differences were observed between the IC
50 values 
obtained after hydrolysis of pre-treated samples with Alcalase 
or collagenase. Alcalase hydrolysates of PT and HT bovine 
lung had PEP IC50 values of 3.62 ± 0.07 and 3.87 ± 0.10 mg/mL, 
respectively. These values were lower than the one obtained 
after hydrolysis of the UT sample (P < 0.05). The PEP IC50 
values of collagenase hydrolysates of PT and HT bovine lung 
were 3.70 ± 0.02 and 4.18 ± 0.11 mg/mL, respectively (Figure 
2). In addition, heat and high-pressure pre-treatments also 
resulted in hydrolysates with lower IC50 values (increased the 
PEP-inhibitory activity of hydrolysates) when using papain. 
Papain hydrolysates of PT and HT samples showed lower PEP 
IC50 values (4.96 ± 0.41 and 5.67 ± 0.47 mg/mL, respectively) 
compared to the IC50 value of the papain hydrolysate of UT 
samples, which was 6.11 mg/mL (P < 0.05).
Effect of pre-treatment and hydrolysis time on the DH
The DH was calculated using the pH-stat technique after 
1, 30, 60, 120, 240 and 1,440 min in each enzymatic 
treatment, and the results are shown in Figure 3. The DH 
was significantly influenced by time (P < 0.001), time × pre-
treatment (P<0.001), time × enzyme (P<0.001) and the 
bovine lung. Hydrolysates generated using non–pre-treated 
lung were also assessed for their PEP-inhibitory activities, 
and the results are shown in Figure 2. No inhibitory activity 
was observed in the unhydrolysed bovine lung proteins. At a 
concentration of 1 mg/mL, the studied hydrolysates generated 
using papain, collagenase and Alcalase, as well as the UT 
bovine lung, showed PEP-inhibitory activity in the range of 
5–10%, compared to the positive control, which inhibited 
PEP by more than 60%. PEP IC
50 values were 6.11 ± 0.70, 
4.70 ± 0.03 and 7.10 ± 0.30 mg/mL for the hydrolysate 
generated with papain, collagenase and Alcalase, respectively.
The percentage of DPP-IV inhibition was calculated for 
Figure 2. In vitro DPP-IV (A) and PEP (B) IC50 values of the studied 
enzymatic hydrolysates. IC50 values represent the means of three 
independent experiments ± standard deviation. For each bioactiv-
ity, bars with different letters have mean values that are significantly 
different (P < 0.05). UT, HT and PT refer to untreated, heat-treated 
and high pressure-treated samples, respectively. DPP-IV = dipeptidyl 
peptidase-IV; PEP = prolyl endopeptidase; IC50 = half-maximal inhibi-
tory concentration.
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interaction between all factors (P < 0.05). The differences 
in the DH were analysed at each time point for the different 
pre-treatments and enzymes used. As expected, when all the 
enzymes were considered together, there was a significant 
effect of hydrolysis time on the DH. The DH increased for all 
enzymatic treatments with time for both the UT and the pre-
treated (HT and PT) samples (P < 0.001). Pre-treatment did 
not affect all the enzymes in the same way. The DH after 24 h 
was measured as 6.1 ± 0.3%, 10.8 ± 0.4% and 13.7 ± 0.3% 
for the papain hydrolysate of the UT, HT and PT lung proteins, 
respectively. High-pressure pre-treatment also increased the 
DH for hydrolysates generated with collagenase. However, 
the observed increase was lower, and after 24 h, the DH was 
6.4 ± 0.3%, 7.6 ± 0.1% and 6.9 ± 0.1% for the hydrolysates 
of UT, HT and PT samples, respectively. A similar trend was 
observed after 24 h for the Alcalase hydrolysates of UT, 
HT and PT samples, which showed a DH of 28.2 ± 1.8%, 
38.8 ± 2.0% and 39.6 ± 1.2%, respectively. Although a slight 
increase in the DH of the Alcalase hydrolysate of the PT 
sample, compared to the HT samples, was observed, this 
was not significantly different.
Identification of proteins and peptides in pre-treated bo-
vine lung Alcalase hydrolysate
A total of 306 proteins were identified in the bovine lung 
sample (supplementary data). Four types of collagen were 
identified: (i) alpha-1 (P02453|CO1A1_BOVIN) and alpha-2 
(P02465|CO1A2_BOVIN) type I collagen, (ii) alpha-1 
(P02459|CO2A1_BOVIN) type II collagen, (iii) alpha-1 
(P04258|CO3A1_BOVIN) type III collagen and (iv) alpha-I 
(Q7SIB2|CO4A1_BOVIN) and alpha-2 (Q7SIB3|CO4A2_
BOVIN) type IV collagen. Other proteins commonly found 
in blood, such as haemoglobin (P01966|HBA_BOVIN and 
P02070|HBB_BOVIN), fibrinogen (P02672|FIBA_BOVIN, 
P02676|FIBB_BOVIN and P12799|FIBG_BOVIN) and 
bovine serum albumin (P02769|ALBU_BOVIN), as well 
as actin (P63258|ACTG_BOVIN, P60712|ACTB_BOVIN 
and P62739|ACTA_BOVIN) and myosin (Q27991|MYH10_
BOVIN), were also identified.
Discussion
The use of co-products, such as lung or blood, in the food 
industry is not new, and these are staple foods found in the 
diets of persons from several countries (Toldrá et al., 2012). 
However, traditional markets for edible co-products are 
disappearing, and the meat industry is making efforts to add 
value to protein sources beyond their current use as techno-
functional ingredients (Toldrá et al., 2012). As mentioned 
earlier, a potential application of meat co-products is as a 
resource for the generation of bioactive hydrolysates. Most 
Figure 3. Degree of hydrolysis of bovine lung treated with Alcalase 
(A), collagenase (B) and papain (C) over a 24 h period. Results 
represent the means of three independent experiments ± standard 
deviation. Different letters indicate mean values that are significantly 
different for treatments at different times (P < 0.05). UT, HT and PT 
refer to untreated, heat-treated and high pressure-treated samples, 
respectively.
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concentrations ranging from 0.91 to 3.79 mg/mL depending 
on the enzymatic treatment (Sila et al., 2015). This could be 
caused because the study by Sila et al. (2015) used fish-
derived gelatine, which is different from bovine collagen and 
was already partially hydrolysed. In addition, use of different 
enzymes under different conditions results in different peptide 
profiles with different bioactivities.
PEP- and DPP-IV-inhibitory peptides are characterised by 
short lengths (Lawandi et al., 2010; Lacroix and Li-Chan, 
2012). Collagen molecules are composed of a triple helix 
formed by the interaction of three a-chains, which are mainly 
stabilised by hydrogen bonds produced by a repetition of the 
GXY sequence, where X is generally proline and Y is generally 
hydroxyproline (Ichikawa et al., 2010). The number of short 
peptides generated from collagen by enzymatic hydrolysis 
was expected to be limited, and this may be the cause of 
the observed low inhibitory values. Hence, bovine lung was 
pre-treated with high temperature and high pressure to aid 
the enzymatic cleavage of proteins and the release of short 
peptides with potential bioactivities. Treatments with high 
pressure and heat were used previously to aid hydrolysis and 
to increase the biological activity of proteins. For example, 
high-pressure treatment was used previously to generate 
ACE-I-inhibitory peptides from ovalbumin (Quirós et al., 
2007) and lentil proteins (Garcia-Mora et al., 2015), as well 
as for the release of antioxidant peptides from egg (Singh and 
Ramaswamy, 2014), lentils (Garcia-Mora et al., 2015) and 
pea (Girgih et al., 2015).
In this study, high pressure was the most efficient pre-treatment 
used to release DPP-IV-inhibitory peptides from bovine lung 
before hydrolysis with the enzyme Alcalase. Previous studies 
suggested that high pressure is more efficient when compared 
to heat (100 °C) in inducing conformational changes, 
enhancing enzymatic hydrolysis and releasing bioactive 
peptides (Girgih et al., 2015). Results obtained herein are 
similar to those obtained previously, where high pressure 
and Alcalase were found to be the most efficient treatment 
modes for generating ACE-I-inhibitory peptides from bovine 
collagen (Zhang et al., 2013). However, this trend was not 
observed after hydrolysis with papain, in which case heat pre-
treatment was found to be more efficient in aiding the release 
of DPP-IV inhibitors. The IC
50 value obtained for the papain 
generated after pressure treatment was significantly higher 
than that for the hydrolysate obtained after heat treatment 
(P < 0.001). In addition, both heat and high-pressure pre-
treatment resulted in a comparable increase in the DPP-IV-
inhibitory activity of the hydrolysate generated by hydrolysis 
using collagenase. Previous studies also suggested that the 
effect of pre-treatments such as high pressure and heat was 
dependant on the enzymatic treatment (Zhang et al., 2013). 
In this study, the most active DPP-IV-inhibitory hydrolysates 
were generated by hydrolysing pre-treated bovine lung with 
of the biologically active hydrolysates and peptides generated 
from meat co-products to date show antihypertensive, 
antimicrobial and antioxidant activities (Bah et al., 2013; 
Lafarga and Hayes, 2014). A number of DPP-IV- (Gallego 
et al., 2014) and PEP- (Ohmori et al., 1994) inhibitory peptides 
have been isolated from animal sources. In addition, bovine 
lung has been used as a source of antioxidant hydrolysates 
previously (Damgaard et al., 2015). However, to the best of 
our knowledge, this is the first study that has examined the 
potential of bovine lung as a source of DPP-IV and PEP 
inhibitors.
Protein content and amino acid composition
The total protein content of bovine lung and the generated 
hydrolysates was calculated, and the results were comparable 
to those obtained in previous hydrolysis studies where high 
protein yields were obtained from peanut or blood proteins 
(Lafarga et al., 2016). The amino acid composition of bovine 
lung (Table 1) showed the presence of a high concentration 
of glutamic acid, glycine, leucine, lysine, arginine and 
proline. Proline is a key amino acid in DPP-IV- and PEP-
inhibitory peptides (Lawandi et al., 2010). The relatively high 
concentration of collagen and the amino acid residue proline, 
together with the high protein content, of bovine lung suggests 
its potential for use as a resource for the generation of PEP- 
and DPP-IV-inhibitory peptides. No significant differences 
were observed in the protein or moisture content of the 
generated hydrolysates. However, the ash content of the 
hydrolysates generated using Alcalase was higher (P < 0.05). 
This could be caused by the higher amount of NaOH added 
during hydrolysis to keep the pH constant at the optimum of 
the enzyme.
In vitro assessment of bioactivity: effect of pre-treatment 
on the release of DPP-IV- and PEP-inhibitory peptides
The DPP-IV IC
50 value of the hydrolysates generated using 
Alcalase and that of the UT samples was similar to those 
obtained in the study by Sila et al. (2015), who recently 
reported the generation of peptidic hydrolysates from barbel 
skin gelatine with DPP-IV IC50 values ranging between 2.2 
and 3.7 mg/mL depending on the enzymatic treatment used. 
As mentioned earlier, bovine collagen and elastin have 
been suggested as a potential source of DPP-IV inhibitors 
(Minkiewicz et al., 2011). However, although bovine lung is 
a resource rich in collagen and elastin, the in vitro DPP-IV-
inhibitory properties obtained herein were lower than those 
obtained previously from enzymatic hydrolysates of bovine 
proteins, including serum albumin (Lafarga et al., 2016). 
In addition, the PEP-inhibitory activity of the generated 
hydrolysates was also higher than that reported in previous 
studies including enzymatic hydrolysates of barbel skin 
gelatine, which inhibited the activity of PEP by half at 
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DH using Alcalase was caused by an increase in the activity 
of this enzyme on all the proteins contained in the bovine lung 
and not only on collagen.
Previous studies reported an increase in the DH after pre-
treatment. For example, high pressure (300 MPa) was 
previously reported to result in the enhancement of the 
proteolytic efficacy of a number of enzymes, including 
Alcalase, Protamex, Savinase and Corolase 7089, on lentil 
proteins (Garcia-Mora et al., 2015). Moreover, high-pressure 
treatments also increased proteolysis of ovalbumin with 
pepsin, trypsin and chymotrypsin (Quirós et al., 2007) and 
proteolysis of bovine collagen with Alcalase, collagenase, 
thermolysin, pepsin and trypsin (Zhang et al., 2013). Although 
only one high-pressure pre-treatment was tested in this study 
(600 MPa, 3 min), a previous study carried out by Singh and 
Ramaswamy (2014) suggested that the DH was increased 
when both pressure level and pressure holding time were 
increased. In the study carried out by Singh and Ramaswamy 
(2014), the maximum DH was achieved when samples were 
treated at 500 MPa for 15 min (maximum pressure and 
highest treatment time tested). Therefore, we would expect 
an increase in DH with an increase in the pressure treatment 
duration, although this would need to be assessed in vitro. 
For hydrolysates generated with Alcalase, both heat and high-
pressure pre-treatments increased the DH as shown in Figure 
3. Treatment at 100 °C for 30 min was used previously (Girgih 
et al., 2015) for inducing structural changes in pea proteins, 
and although the DH was not measured in that study, the 
authors suggested that the observed increase in 
the antioxidant activity was caused by a favoured release of 
peptides after hydrolysis of the pre-treated sample compared 
to the control (Girgih et al., 2015). In this study, heat was 
more effective in increasing the DH than high pressure after 
hydrolysis with collagenase. This aligns with a previous study 
in which both heat and high pressure were applied to bovine 
collagen, and thereafter boiling of collagen was found to give 
rise to the highest DH as well as ACE-I-inhibitory activity 
(Zhang et al., 2013). However, this trend was not observed 
in this study during hydrolysis using papain, whereby high-
pressure pre-treatment resulted in the highest increase in the 
DH after 24 h.
Results obtained in this study suggested that heat and high-
pressure pre-treatments can increase the DH of the papain, 
collagenase and Alcalase hydrolysates of bovine lung over 
a 24 h period, and this increase was found to be enzyme 
dependent. In addition, the observed increase in the DH was 
not directly related to an increase in bioactivity. For example, 
in the case of HT samples, the DH obtained after hydrolysis 
with Alcalase was five fold bigger than that obtained after 
hydrolysis with collagenase. However, the DPP-IV- and PEP-
inhibitory bioactivities of the enzymatic hydrolysate of Alcalase 
were only slightly higher (P<0.05). Similar results were 
Alcalase. The IC
50 values of the Alcalase hydrolysates of 
PT and HT bovine lung were comparable to those obtained 
previously by proteolytic or microbial hydrolysis of East Asian 
azuki bean, where a 10-kDa fraction showed 52% inhibition 
of DPP-IV at a concentration of 1 mg/mL (Patil et al., 2015). 
The hydrolysates generated using Alcalase in this study 
were more active than DPP-IV-inhibitory hydrolysates 
reported previously in the literature, including a tuna cooking 
juice hydrolysate generated using fungal proteases, which 
inhibited DPP-IV by 45.2% at a concentration of 2 mg/mL 
(Huang et al., 2012).
Although numerous bioactive peptides with PEP-inhibitory 
activities have been isolated from natural sources, including 
wine (Yanai et al., 2003), bovine brain (Ohmori et al., 
1994) and cheese (Sorensen et al., 2004), the number of 
active hydrolysates reported in the literature is still limited. 
Combinations or mixtures of peptides were suggested to 
ensure a better nutraceutical effect than single peptides 
(Sorensen et al., 2004). The PEP-inhibitory value of the 
Alcalase hydrolysate of PT bovine lung obtained in this study 
was comparable to that of chemically synthesised peptides, 
including MPPPLPARVDALD with an IC
50 value of 38.4 mM 
(Ohmori et al., 1994) and to a peptidase hydrolysate of barbel 
skin, which had an IC50 value of 3.79 mg/mL (Sila et al., 
2015). However, a number of hydrolysates generated by Sila 
et al. (2015), including the Alcalase, trypsin and neutrase 
hydrolysates of fish gelatine, showed lower IC50 values.
Overall, the generated enzymatic hydrolysates of UT bovine 
lung showed low DPP-IV- and PEP-inhibitory activities. 
However, heat and pressure treatment increased the DPP-IV- 
and PEP-inhibitory activities of bovine lung after hydrolysis 
with selected enzymes, and their in vitro inhibitory values 
were comparable to previously reported hydrolysates with 
PEP- and DPP-IV-inhibitory properties.
Effect of pre-treatment and hydrolysis time on the DH
A secondary aim of this study was to evaluate the effect of heat 
and high-pressure pre-treatments on the DH. In this study, 
high pressure was the most efficient pre-treatment among 
those studied in aiding the release of peptides using papain. 
The optimum temperature used for hydrolysis with papain 
was already high, probably denaturing part of the collagen 
triple helical structure and other proteins. High-pressure pre-
treatment also increased the DH for hydrolysates generated 
with collagenase. However, the observed increase was 
lower, and after 24 h, the DH was 6.4 ± 0.3%, 7.6 ± 0.1% 
and 6.9 ± 0.1% for hydrolysates of UT, HT and PT samples. 
It is probable that pre-treatment of bovine lung facilitated the 
action of collagenase on peptide bonds of bovine collagen but 
did not cleave other proteins such as actin or haemoglobin 
present in the sample. In addition, Alcalase is a non-specific 
enzyme, and it is probable that the observed increase in the 
20
Irish Journal of Agricultural and Food Research
Table 2. Collagen-derived peptides released from pressure-treated bovine lung by the action of Alcalase
Amino acid sequence Protein Accession Position MW (Da) PeptideRanker score
GFPGADGVAGPK P02453|CO1A1_BOVIN 493–505 1,072.19 0.70
GADGAPGKDGVRGL P02453|CO1A1_BOVIN 751–764 1,269.38 0.76
GADGAPGKDGVR P02453|CO1A1_BOVIN 751–762 1,099.17 0.53
GDDGEAGKPGRPGERGPP P02453|CO1A1_BOVIN 229–246 1,748.83 0.60
GAVGPAGKDGEAGAQ P02453|CO1A1_BOVIN 604–618 1,284.35 0.26
GERGFPGERGVQ P02453|CO1A1_BOVIN 676–687 1,288.39 0.32
GDRGDAGPK P02453|CO1A1_BOVIN 742–750 871.91 0.41
DGAPGKDGVR P02453|CO1A1_BOVIN 753–762 971.04 0.45
DRGDAGPK P02453|CO1A1_BOVIN 743–750 814.85 0.38
GDRGIKGH P02453|CO1A1_BOVIN 1102–1109 838.92 0.40
AGEEGKRGARGEPGPA P02453|CO1A1_BOVIN 461–476 1,538.64 0.36
TGSPGSPGPDGK P02453|CO1A1_BOVIN 539–550 1,056.10 0.51
GAPGDKGEAGPS P02453|CO1A1_BOVIN 775–786 1,042.04 0.40
SGEPGAPGSK P02453|CO1A1_BOVIN 432–441 885.93 0.41
DGAPGKDGVRGL P02453|CO1A1_BOVIN 752–763 1,141.25 0.73
KDGVRGLTGPI P02453|CO1A1_BOVIN 757–767 1,112.29 0.28
GFPGER P02453|CO1A1_BOVIN 679–684 661.72 0.76
FPGER P02453|CO1A1_BOVIN 680–684 604.66 0.73
SGERGPP P02453|CO1A1_BOVIN 990–996 698.73 0.52
GEKGAPGADGPA P02453|CO1A1_BOVIN 931–942 1,026.07 0.37
KGDRGDAGPK P02453|CO1A1_BOVIN 741–750 1,000.08 0.33
GPRGETGPAGRPG P02453|CO1A1_BOVIN 907–919 1,208.30 0.47
FLPQPPQEK P02453|CO1A1_BOVIN 1199–1207 1,083.25 0.41
GERGFPGLP P02453|CO1A1_BOVIN 967–975 929.04 0.78
FGFDGDFYRA P02465|CO1A2_BOVIN 1108–1117 1,194.27 0.83
GDQGPVGR P02465|CO1A2_BOVIN 821–828 784.83 0.53
GFDGDFYRA P02465|CO1A2_BOVIN 1109–1117 1,047.09 0.82
GEKGETGLR P02465|CO1A2_BOVIN 653–661 946.03 0.20
GEDGHPGKPGRPGER P02465|CO1A2_BOVIN 140–154 1,545.63 0.62
GIDGRPGPIGPA P02465|CO1A2_BOVIN 470–481 1,106.25 0.60
GRPGPIGPA P02465|CO1A2_BOVIN 473–481 820.95 0.69
DGDFYR P02465|CO1A2_BOVIN 1111–1116 771.78 0.78
GKEGPVGLPGIDGRP P02465|CO1A2_BOVIN 461–475 1,448.64 0.60
GLPGADGR P02465|CO1A2_BOVIN 404–411 741.80 0.49
GFDGDFYR P02465|CO1A2_BOVIN 1109–1116 976.01 0.87
GKEGPVGLPGID P02465|CO1A2_BOVIN 461–472 1,138.29 0.39
AGARGSDGSVGPVGPA P02465|CO1A2_BOVIN 229–244 1,354.44 0.35
RGEVGLPGLSGPV P02465|CO1A2_BOVIN 280–292 1,237.42 0.39
GEEGKRGSTGEIGPA P02465|CO1A2_BOVIN 374–388 1,444.52 0.23
GSVGEPGPL P02465|CO1A2_BOVIN 887–895 811.89 0.61
GERGPPGESG P02465|CO1A2_BOVIN 587–596 941.95 0.28
GDKGEPGDKGPR P02465|CO1A2_BOVIN 1004–1015 1,212.28 0.52
SGLPGER P02465|CO1A2_BOVIN 637–643 714.78 0.49
EGPVGLPGIDGRP P02465|CO1A2_BOVIN 463–475 1,263.42 0.53
GERGLPGVA P02465|CO1A2_BOVIN 878–886 854.96 0.31
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(MW) of most of the peptides identified in this study ranged 
between 600 and 1,200 Da. As mentioned earlier, PEP- 
and DPP-IV-inhibitory peptides are short in length (Lawandi 
et al., 2010; Lacroix and Li-Chan, 2012). Because of the 
sequence diversity of short peptides, de novo sequencing 
or the use of standards for matching the accurate masses 
and retention times is difficult and time consuming. The use 
of database searches for peptide identification is commonly 
used. However, current search algorithms are often limited 
to peptides containing more than four amino acids in 
length (Tang et al., 2014). Shorter peptides do not produce 
a sufficient number of unique fragment ions and are not 
retained well on LC columns, making their identification very 
complicated (Tang et al., 2014). Many efforts are being put into 
the identification and quantification of di-, tri-, and other small 
peptides. For example, Tang et al. (2014) recently published 
a novel database search methodology for the identification of 
di- and tripeptides from complex biological samples based on 
the use of MS/MS spectra of both unlabelled and dimethyl-
labelled peptides.
Table 2 lists the identified unique collagen-derived peptides 
generated from PT bovine lung by the action of Alcalase, 
obtained for PT samples, whereby no significant differences 
were observed between the IC
50 values of the hydrolysates 
generated using Alcalase and collagenase, and the DH of 
the former was five times bigger than the latter. This was 
caused by a higher content of peptides derived from collagen 
in the hydrolysate generated using collagenase compared to 
the one generated using Alcalase, which contains a larger 
number of peptides but which were generated from proteins 
such as haemoglobin or serum albumin.
Identification of proteins and peptides in pre-treated bo-
vine lung Alcalase hydrolysate
Identification of small peptides in biological or food samples 
is mainly done by MS coupled with LC. In this study, a 
total of 2,350 peptides were identified by LC-MS/MS in the 
Alcalase hydrolysate of PT lung proteins (supplementary 
data). The majority of these (73.5%) were cleaved from type 
I collagen, which is the most common type of collagen in the 
body (approximately 90%) and is found in the skin, tendon, 
bones and internal organs including the lungs (Di Lullo et al., 
2002). Numerous peptides were also generated from bovine 
haemoglobin (323) and actin (373). The molecular weight 
Amino acid sequence Protein Accession Position MW (Da) PeptideRanker score
FDGDFYRA P02465|CO1A2_BOVIN 1110–1117 990.04 0.83
DGNKGEPGVV P02465|CO1A2_BOVIN 616–625 971.03 0.22
FDGDFYR P02465|CO1A2_BOVIN 1110–1116 918.96 0.89
KEGPVGLPGID P02465|CO1A2_BOVIN 462–472 1,081.23 0.31
GEVGLPGL P02465|CO1A2_BOVIN 281–288 740.85 0.52
AGPAGERGEQGAP P02459|CO2A1_BOVIN 647–659 1,196.24 0.32
GERGEQGAP P02459|CO2A1_BOVIN 651–659 899.92 0.13
GERGAPGEKGEG P04258|CO3A1_BOVIN 669–680 1,143.18 0.27
GERGVPGF P04258|CO3A1_BOVIN 327–334 817.90 0.58
GVDGAPGKDGPR P04258|CO3A1_BOVIN 594–605 1,125.21 0.53
GLPGGPGLR P04258|CO3A1_BOVIN 372–380 822.96 0.84
GERGGPGGPGPQ P04258|CO3A1_BOVIN 438–449 1,065.11 0.43
VDGAPGKDGPR P04258|CO3A1_BOVIN 595–605 1,068.15 0.48
GSSGVDGAPGKDGPR P04258|CO3A1_BOVIN 591–605 1,356.41 0.56
RGEPGPQGHAGAP P04258|CO3A1_BOVIN 212–224 1,230.31 0.44
GNRGERGSEGSP P04258|CO3A1_BOVIN 1011–1022 1,202.21 0.13
ERGVPGF P04258|CO3A1_BOVIN 328–334 760.85 0.55
GVPGIAGPR P04258|CO3A1_BOVIN 630–638 822.96 0.62
KGEPGSSGVDGAPGKDGP P04258|CO3A1_BOVIN 587–604 1,611.69 0.44
GIPGAPGLI P04258|CO3A1_BOVIN 246–254 793.96 0.73
GVPGFRGPA P04258|CO3A1_BOVIN 330–338 856.98 0.72
TTAPLPMMPVAEEDIRPY Q7SIB3|CO4A2_BOVIN 84–101 2,031.37 0.16
EDIRPY Q7SIB3|CO4A2_BOVIN 96–101 791.86 0.27
PeptideRanker is available at http://bioware.ucd.ie/~compass/biowareweb/. MW = molecular weight.
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